loading page

AstraZeneca COVID-19 vaccine: A possible risk factor for Stroke, Case Series
  • +5
  • Amira Siddig Omer,
  • Abbasher Hussien Mohamed Ahmed,
  • Khabab Mohamed Ahmed,
  • Abdallah M. Abdallah,
  • Mohamed Malekaldar,
  • AlHussien Abbasher,
  • Mohammed Abbasher,
  • Abubaker Alsedig Abbasher
Amira Siddig Omer
Al-Neelain University Faculty of Medicine

Corresponding Author:amirasiddig121@gmail.com

Author Profile
Abbasher Hussien Mohamed Ahmed
University of Khartoum Faculty of Medicine
Author Profile
Khabab Mohamed Ahmed
University of Khartoum Faculty of Medicine
Author Profile
Abdallah M. Abdallah
University of Bahri, Faculty of medicine
Author Profile
Mohamed Malekaldar
Omdurman Teaching Hospital
Author Profile
AlHussien Abbasher
AlYarmouk college
Author Profile
Mohammed Abbasher
Al-Neelain University Faculty of Medicine
Author Profile
Abubaker Alsedig Abbasher
Zamzam University college
Author Profile

Abstract

Cerebrovascular accident (CVA) is one of the commonest neurological deficits. There is a well-known association between COVID-19 and stroke. We present a case series of Sudanese patients who developed CVA after receiving the AstraZeneca COVID-19 vaccine suggesting a relationship between the vaccine and CVA.
10 Dec 2021Submitted to Clinical Case Reports
10 Dec 2021Submission Checks Completed
10 Dec 2021Assigned to Editor
22 Dec 2021Reviewer(s) Assigned
24 Dec 2021Review(s) Completed, Editorial Evaluation Pending
20 Jan 2022Editorial Decision: Revise Minor
02 Feb 20221st Revision Received
03 Feb 2022Submission Checks Completed
03 Feb 2022Assigned to Editor
03 Feb 2022Review(s) Completed, Editorial Evaluation Pending
13 Feb 2022Reviewer(s) Assigned
17 Mar 2022Editorial Decision: Revise Minor
24 Mar 20222nd Revision Received
13 Apr 2022Submission Checks Completed
13 Apr 2022Assigned to Editor
13 Apr 2022Review(s) Completed, Editorial Evaluation Pending
26 Apr 2022Reviewer(s) Assigned
21 May 2022Editorial Decision: Revise Minor
21 May 20223rd Revision Received
23 May 2022Assigned to Editor
23 May 2022Submission Checks Completed
23 May 2022Review(s) Completed, Editorial Evaluation Pending
03 Jun 2022Editorial Decision: Accept